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A Study of the Synergy of Microwave Coagulation and 
Streptococcal Preparation (OK-432) in Experimental 
Tumor in Regard to the Interleukin 2 
Producing Activity. 
HIROKI Y AMAUE、MASAHARUKATSUMI, KATSUYOSHI TABUSE, YOJ! TABUSE.、
HIROMU EGAWA, H!ROYUKI NOGUCHI, YUGO NAGAI、
y ASUHITO KOBA y ASH! and KAZUNARI MORI 
Department of Gastroenterological Surgery, Wakayama ;¥Jedir:d College 
(Director: Prof. Dr. MASAHARU KAT5Dll) 
In our department, Microwave Tissue Coagulator (MTC) has been maked use of the coagu・
lation for the malignant tumor that expects to destroy the tumor lesions and to increase the 
anti-tumor immunity. This report revealed whether the interleukin 2 (IL-2) producing activity 
of spleen cells was augmented in use of the microwave coagulation (MC) with OK-432 in 
expenmental tumor, or not. 
The. IL-2 activity of spleen cells, ratio of tumor growth and viability percentage were experi-
mented in BALB/c mice after MC and/or OK-432 injection toward the transplanted Meth A 
fibrosarcoma. All experimental mice were injected OK-432 subcutaneously (s.c.), after that, 
mice were divided to the following groups; Group 1 control (no treatment), Group 2: OK-432 
s.c., Group 3: Group 2十MC toward the tumor, Group 4: Group z+OK-432 injected 
intratumorously (i.t.), Group 5: Group 2+MC, OK-432 i.t., Group 6: Group 5十OK-432s.c. 
after treatment. Tumor growth of each group was investigated every few days. Viability 
Key words: Microwave coagulation, Streptococcal preparation (OK-432), Interleukin 2. Lymphokine, Immuno-
therapy. 
索引語：マイクロ波凝固， OK-432, インターロイキン2' リンホカイン，免疫療法
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percentage of each group was compiled statistically by Kaplan-Meyer’s method. IL-2 producing 
activity of spleen cells was searched by the method of Gillis. 
The tumor growth in Group 3, 5 and 6 was significantly inhibited as compared with that of 
Group 1, 2 and 4. Viability percentage in Group 3, 5 and 6 was significantly higher as compared 
with that of Group 1. From the view point of IL-2 producing activity of spleen cels, immunity 
of Group 5 and 6 was more augmented. 
Depending upon the facts above mentionedヲtheclinical application was done. The patients 
of study were inoperable gastroenterological cancer bearers. The patients treated by both 
MTC and OK 432 i.t. were improved in symptoms and signs‘stil more, IL-2 procucing activity 
of peripheral mononuclear cells was more augmented as compared with that of the patients of 
either MTC or OK-432 i.t. alone. 
As mentioned above, synergy of MC、andOK 432 toward the malignant tumor was proved 










してきた．また Streptococcalpreparation (OK-432) 
は，腫場細胞に対しての直接的殺細胞効果23'19>とBio回






また Interleukin2 （以上 IL-2と略す）は PHA刺激















化牛胎児血清（fetalcalf serum, FCS, GIBCO Dia-
gnostics Laboratories, Madison, Wilconsin）を添加さ
れた培養液 RPMI-1640(Nissui Pharmaceutical Co, 










継代培養中の Meth-Aを Eagle’sMEM (Niss山
Pharmaceutical CO, LTD, TOKYO）で3回洗浄後，
Q. 04% Trypan blue dye exclusion法山にて生細胞を
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Fig. 1. Experimental protocol 
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(3）実験方法（Fig.l) 
Fig. l IC実験のプロトコールを示した.Group 1 (n 




ml Ir溶解した OK-4321. 0 KEずつ皮下注射し，そ
の後14日めに， Group2 (n=l3）は生食lm！腫蕩内局
注群， Group3(n=22）は 25W,15秒間で3回腫蕩を
MTC処置した群， Group4 (n = 22）は生食 lmlに溶
解した OK-4323司OKEを腫場内投与した群， Group
5 (n=23）は MTC処置後残存する腫蕩へ OK432 
3.0KEを局注した群，および Group6(n=22）は
Group 5 Iζ加えてさらに処置後1週間に3回， OK-







1640 IC FCS （最終濃度10%),5×10-sM 2 mercapto・
ethanol, 100 U/ml penicillin と 100μg/ml strepto・ 
mycin (GIBCO, Laberatories, Madison, Wisconsin）お
よび0.3 g/1000 ml glutamine (Nissui Pharmaceutical 
Co, LTD, TOKYO）を加え7%NaHC03で pH7.1 
～7.4に調整したものを用いた．単核球浮遊液を96穴
平底7 イクロプレート（Corning,No. 25820）に lOμg/
第55巻







を可及的に単細胞化した後， tris-bufferedNH.Cl (pH 
7. 2）で赤血球を溶解し，単核球浮遊液を作成後 ME
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The tumor volume of Group 1, control group and Group 2 increased day by day. On the 18th day 
after tumor transplantation. the tumor volume of Group 3. 4 5 and 6 was suppressed as compared 
with that of Group 1 and 2 (P・ 0.01. and disparity in volume was similarly recognized between 
Group 4 and Group 3 . S 6 IP・ 0.01. 
On the 25th day after tumor transplantation. the tumor volume of Group 3, 5 and 6 was suppressed 
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ml concanavarine A, Con A, type IV (Sigma chemical 
company, ST. LOUIS, USA）を加えて， 24時間，
37。c,5'ぢC02下に培養した.24時間培養後の super-
natant，すなわち ConA-sup.の IL-2活性を測定した．




10 μg/ml, Con Aを加えて48時間培養後，その ConA『
sup.を standardIL 2 (TCGF）として用いた．
ii) Cloned mouse cytolytic T lymphocyte line 
(CTLL）の作成
IL 2 dependent Killer T cell line (CTLL）は，






FCS加 CMで調整した 1×105/mlCTLLを 100μ1
と ConA-sup. 100 ulを加え24時間培養した．培養終
了5時間前lと各 wellあたり lμCiの 3HThymidine 
(New England Nuclear, Boston, Massachusetts）を加
え， glassfiber filterで cellharvest後，キシレン液体
シンテレーション法にて DNA合成能（3HThymi-
dine uptake）を測定した．測定はtriplicateで施行し，
平均 cpmを求めた.IL-2 1 unitは standardIL-2の
長高値と最低値の平均値の cpmとし，測定された IL
-2活性は以下の式で求めた．
cpm of sample cpm of minimum 








For each group. on the 30th day alter tumor transplantation. 5X tO・MethA were rechallenged ontraperitoneally 
In Group t. al mice d暗dles than 37 days 
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れ， Group1, 2と有意差を認めた.Group 5, MTC + 
OK-432局注群では Group3よりさらに腫場体積は
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Treatment tumor transplantation 
Fig. 4. Interleukin 2・producingactivity of spleen cels 
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The left figure shows the additional effect of OK-432 to microwave coagulation. and the right shows the additional effect of 
microwave coagulation to OK-432. Both figures show the IL-2 activity of Group 5 1nmore augmented as compared with that of 
Group 3 or4 through the experimental course 
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Fig. 5. Synergy of microwave coagulation and OK-432 for interleukin 2-producing activity 
では再上昇し， terminalstage においても良好な産生
































glutinine (PHA-P, Difeo laboratories. Detroit Michi-
gan USA) 10 μg/mlで24時間刺激した．その培養上清，
すなわち PHA-sup.100μ1あたりの IL2活性を前
述の如く CTLL,standard IL 2を用いて測定した．
m. 結果（Fig.6)
IL-2産生能が処置により上昇した症例は， Group
(1): MTC処置群では3例中2例， Group(2):OK-432 
局注群では4例中3例，およびGroup(3）：両者併用群
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Table 1. The clinical C品目 examined
All c回目 wereinoperable gastroenterological 
cancer l>earers. 
Group (1): :¥licrowa¥'e coagulation 
No Age Sex Diagnosis 
1. 70 五I esophageal cancer 
2. 74 F gall uiadder cancer 
3. 84 ¥I esophageal cancer 
Group (2): OK-432 intratumoral or intraarterial 
m1ect10n 
No Age Sex Diagnosis 
4. 68 pancreatic cancer 
5. 65 :¥[ hepatocellular carcinoma 
6. 75 F gastric cancer 
7. 76 :¥[ hepatocellular carcinoma 
Group (3）・ 'Vlicrowavecoagulation + OK・432
injection 
'.'io Age Sex D阻gnosis
8. 62 :VI pancreatic cancer 
9. 58 ¥I gall bladder cancer 
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7 . hepat。cellular ca 
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bef。re After bef。re After bef。re ’ After
Fig. 6. Interleukin 2-producing activity of peripheral mononuclear els in the clinical cases 
IL-2-producing activity of case 9 and 10 in Group (3) was augmented, and stil 




















BALB/c ＜ ウスに syngeneicMeth A fibrosarcoma 
を移植し担腫場マウスを作成し， OK-432前感作の後，
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